Medicare AdvantageCoverageHigh impact
Cryoablation - Medicare Advantage (Revised)
Humana·Dermatology, Oncology, Urology +3 more·Medicare Advantage
Effective date
Aug 3, 2026
We identified it
Jul 30, 2026
Summary
Humana Medicare Advantage has revised its cryoablation coverage policy (HUM-1065-003), effective August 3, 2026. The policy establishes specific medical necessity criteria for cryoablation across multiple indications including malignant skin lesions, liver tumors, lung tumors, and renal cell carcinoma, with defined CPT codes and clinical requirements. Billing teams must ensure claims meet the documented criteria or face denials.
Action Required
By August 3, 2026: Billing team must implement coverage validation for all cryoablation claims submitted to Humana Medicare Advantage. Update billing software to enforce the specific medical necessity criteria outlined in policy HUM-1065-003 for each indication (malignant skin lesions, liver tumors, lung tumors, renal cell carcinoma). For malignant skin lesions (CPT 17261-17264): verify documentation confirms low-risk BCC/cSCC and patient is not a candidate for surgical resection or radiation therapy. For liver tumors (CPT 47371, 47381, 47383): confirm either single HCC <3cm or small metastatic tumors with ablatable margins. For lung tumors (CPT 32994): verify Stage 1 NSCLC, patient non-surgical candidate, and tumor <3cm, OR for metastatic tumors confirm disease control at original sites. For renal cell carcinoma (CPT 50250, 50542, 50593): confirm biopsy-proven diagnosis and meet one of the specified criteria. Additionally, cross-reference applicable MAC Local Coverage Determinations (L33813, L33445, NCD 230.9) based on patient jurisdiction. Providers must include supporting clinical documentation on all claims. Claims without proper medical necessity documentation will be denied. Front desk and prior authorization staff should flag any cryoablation requests for immediate review against these criteria.